Key facts
- This page summarizes Jonathan W. Ayers's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 13 May 2022, 17:36.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Award
Options Exercise
Additional SEC filing notes
Footnote F1
Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.
Footnote F3
Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier.
Footnote F4
Not applicable.